The multidrug resistance (MDR) phenotype is characterised by: (1) cross-resistance between structurally and functionally unrelated drugs such as anthracyclines and vinca alkaloids; (2) decreased intracellular drug levels in resistant cells compared with wild type cells; (3) overexpression of a 170 kDa plasma membrane glycoprotein called P-glycoprotein; and (4) the ability of a number of amphipathic drugs to modulate resistance (recently reviewed by Bradley et al., 1988) . These modulators are considered to act by increasing cytotoxic drug levels in resistant cells by inhibiting their energy dependent efflux. It was therefore of interest to examine whether modulators had similar energy dependent accumulation patterns as the cytotoxic drugs in wild type and resistant cells, a finding which would be consistent with competitive inhibition for drug efflux. Verapamil, the most studied modulator which was first described by Tsuruo et al. (1981) and azidopine, a dihydropyridine analogue which has the advantage of being able to photoaffinity label P-glycoprotein (Safa et al., 1987) were chosen for study.
Materials and methods

Cell lines
Wild type EHR2 and daunorubicin resistant EHR2/DNR + cells have previously been described in detail (Dan0, 1971 (Dan0, , 1973 Skovsgaard, 1978) . EHR2/DNR + cells have all the characteristics associated with the multidrug resistance phenotype including cross resistance to vinca alkaloids and decreased drug accumulation (Skovsgaard, 1978) , modulation by verapamil (Friche et al., 1987) , and increased expression of P-glycoprotein (Sehested et al., 1989a (Skovsgaard, 1977) . Experiments with azidopine were performed in the dark. When depletion of cellular energy was required, glucose was omitted and 10 mM sodium azide added to the medium. After incubation with either 3H-azidopine, 3H-verapamil or '4C-verapamil cells were washed twice in ice-cold Ringer's solution by centrifugation, and the final pellet solubilised with 1 ml of 0.1% v/v Nonidet P40 overnight (solubilisation with either KOH or HCI yielded similar results). Control experiments with pelleting through silicone oil as described by Yusa et al. (1989) were also performed. Daunorubicin accumulation was measured by spectrofluorometry as previously described (Skovsgaard, 1977) .
Clonogenic assay This was performed as previously described (Roed et al., 1987) . Only continuous incubation with drug for 3 weeks was used.
Photoaffinity labelling with azidopine Plasma membrane vesicles from EHR2 and EHR2/DNR + were photolabelled with 3H-azidopine as described by Safa et al. (1987) . Photolabelled proteins were analysed by SDS-PAGE (9% gel), fluorography and photodensitometry. Immunoprecipitation of P-glycoprotein was performed as described by Mukhopadhyay and Kuo (1989) using the C219 monoclonal antibody against P-glycoprotein purchased from Centocor (Belgium).
Results
Accumulation of verapamil, azidopine and daunorubicin in whole cells Figure 1 shows that the accumulation of '4C-verapamil in EHR2 and EHR2/DNR + is similar over the course of 2 h. Furthermore, reducing the cellular energy generation by omission of glucose and addition of sodium azide demonstrates that deprivation of energy leads to very low levels of '4C-verapamil accumulation in both cell lines. This is further illustrated in Figure 2 , where the addition of 10 mM glucose after 30 min of deprivation leads to a rapid increase in '4C-verapamil accumulation. Accumulation of 3H-verapamil (5 pM) at 60 min, 37°C was also equal in both cell lines and was likewise reduced by deprivation of cellular energy as accumulation of the '4C-isotope (not shown). The effect of daunorubicin, vincristine and azidopine on verapamil accumulation is shown in Figure 3 . Daunorubicin inhibited verapamil accumulation in EHR2/DNR + by 15% at a 10-fold molar excess. The greater inhibition in EHR2 cells is presumably due to increased daunorubicin toxicity in the wild type cells. The decrease in verapamil accumulation in both EHR2 and EHR2/DNR + cells during simultaneous azidopine incubation can also be ascribed to azidopine toxicity at the 25 ,.M level. However, vincristine in 10-25-fold molar excess induced a small but statistically significant increase in verapamil accumulation in EHR2/DNR + cells only. Alteration of the cation composition in the incubation medium by exchanging Na+ for K+ up to 80 mM K+ or by addition of Ca2+ from 0 to 32 mM had no effect on verapamil accumulation (not shown). Neither did the use of a Tris instead of a phosphate buffer or when incubation media and pelleting and extraction procedures according to Broxter- Figure 4 in that accumulation is rapid and with only minor effect of manipulation of cellular energy levels. The decrease in azidopine levels over time in medium containing sodium azide in both cell lines suggest that this is due to an additive toxic effect. However, as for verapamil, steady state azidopine levels are similar in both cell lines. Azidopine increased daunorubicin accumulation in EHR2/DNR + cells in a dose dependent manner ( Figure 5 ). Finally, though a 10-fold molar excess of daunorubicin had no effect on azidopine accumulation, there was a slight but statistically significant dose dependent effect of verapamil in 5-25-fold molar excess on azidopine accumulation in EHR2/DNR + cells but not in EHR2 cells (Figure 6 ). Vincristine in 10-fold molar excess also significantly increased azidopine accumulation in EHR2/DNR + cells ( Figure 6 ). Photoaffinity labelling and immunoprecipitation of P-glycoprotein 3H-azidopine photolabelled a 170 kDa protein in plasma membrane vesicles from EHR2/DNR + only (Figure 7 , lanes 1 and 2), and immunoprecipitation with monoclonal antibody C219 confirmed azidopine labelling of P-glycoprotein ( Figure 7, lane 7) . In repeated experiments, vincristine inhibited labelling of P-glycoprotein as measured by densitometry scans by 41-80% at 100-fold molar excess (e.g. Figure 7 , lane 5). Verapamil inhibited azidopine labelling by 38-73% at 100-fold molar excess (e.g. Figure 7 , lane 4), while daunorubicin did not inhibit azidopine labelling in any of three experiments at 100-fold molar excess (e.g. Figure 7 , lane 6).
Clonogenic assay Both verapamil and azidopine act as typical multidrug resistance modifiers in EHR2/DNR + cells (Figure 8) 
Discussion
The MDR1 gene mRNA is overexpressed in a number of human tumours (Fojo et al., 1987) and the modulation of the MDR phenotype could therefore well have clinical importance. The overexpression of P-glycoprotein appears to be essential to the MDR phenotype of increased drug efflux (Bradley et al., 1988) and the relationship between modulator and P-glycoprotein has therefore received a great deal of attention. Verapamil is the best documented modulator since its description by Tsuruo et al. (1981) , and has also been shown to inhibit daunorubicin efflux and modulate resistance in our EHR2/DNR + cell line (Friche et al., 1987 and Figure 8) . Verapamil has been reported to have an accumulation pattern typical of drugs in the MDR family, i.e. decreased accumulation in MDR cells compared to wild type cells in medium containing glucose (Broxterman et al., 1988; Cano-Gauchi & Riordan, 1987; Kessel & Wilberding, 1984; Warr et al., 1988; Yusa and Tsuruo, 1989) and increased accumulation in resistant cells after deprivation of cellular energy sources (Kessel & Wilberding, 1984) . However, as demonstrated in Figures 1 and 2 , the accumulation pattern of verapamil is similar in both EHR2 and EHR2/DNR + cells and furthermore shows the opposite reaction to deprivation of cellular energy to that of MDR drugs like daunorubicin and vincristine in the same cell lines (Skovsgaard, 1978) . This difference in the verapamil accumulation pattern in EHR2 and EHR2/DNR + cells compared with other described MDR cell lines is hardly due to experimental procedures as we have tried a variety, including copies of those of Broxterman et al. (1988), Kessel and Wilberding (1984) and Yusa and Tsuruo (1989) and have furthermore also used two different verapamil isotopes. It is also unlikely that the lack of a demonstrable verapamil efflux 'pump' in EHR2/DNR + is due to its being overshadowed by a more rapid influx as influx is slower than for daunorubicin (Figure 1 and Skovsgaard, 1978). Interestingly, several MDR cell lines have been reported to be hypersensitive to verapamil itself (CanoGauchi & Riordan, 1987; Twentyman et al., 1986; Warr et al., 1988) . This is not the case for EHR2/DNR + which has a higher IC50 value of 90ZM verapamil compared to 55 tAM for EHR2 in a 3-week continuous incubation clonogenic assay, a cross resistance which is clearly not caused by reduced accumulation (Figure 1) . Recently other murine MDR cell lines which are also cross resistant to verapamil have been described (Reeve et al., 1989) . The dihydropyridine analogue azidopine has received great interest in characterisation of the MDR phenotype since its original description by Safa et al. (1987) as it is inherently photoreactive (Bruggemann et al., 1989; Kamiwatari et al., 1989; Schurr et al., 1989; Yang et al., 1988; Yoshimura et al., 1989) . However, to our knowledge, the modulating properties of azidopine as well as its own cellular accumulation have not been previously described. As shown in Figures 5 and 8 , azidopine is a typical modulator with an efficiency exceeding that of verapamil in EHR2/DNR + cells ( Figure 5 and Friche et al., 1987) , though it is considerably more cytotoxic by itself than verapamil (Figure 8 ). It typically photolabels P-glycoprotein in plasma membrane vesicles from EHR2/ DNR+ cells (Figure 7 ) as previously described in other MDR cell lines (Safa et al., 1987) . Thus, though azidopine binds to P-glycoprotein, there is no difference in its accumulation between wild type and resistant cells (Figure 4) . In fact, the accumulation of azidopine is remarkably similar to that reported for nitrendipine (Kessel, 1986) . Similar results have been described for the modulating bisbenzylisoquinoline alkaloid cepharanthine, which is also accumulated in equal amounts in wild type and resistant cells (Shiraishi et al., 1987) and which also inhibits azidopine labelling of Pglycoprotein (Asoh et al., 1989; Kamiwatari et al., 1989) . Yusa and Tsuruo (1989) reported that a 1,740-fold excess of vinblastine was able to increase 3H-verapamil accumulation by 40% in MDR K562/ADM cells thus reaching to a level of 43% of that of wild type K562 cells. We also found that vincristine significantly increased verapamil accumulation in EHR2/DNR + cells (Figure 3 ) and furthermore that vincristine and verapamil also increased azidopine accumulation ( Figure 6 ) to levels which exceeded those found in wild type EHR2 cells. This curious phenomenon of drug levels in MDR cells exceeding those in wild type cells has not, to our knowledge, previously been described. It is not readily explained, but could be due to altered intracellular distribution of these modulating drugs caused by activation of Pglycoprotein.
Recently, two azidopine binding sites on P-glycoprotein have been detected (Bruggemann et al., 1989) , with the C terminal one being mostly labelled (Yoshimura et al., 1989) .
Azidopine photolabelling of P-glycoprotein in EHR2/ DNR + is inhibited by a large (100-fold) molar excess of both vincristine and verapamil to roughly the same extent as described by Safa et al. (1987) , but not by daunorubicin ( Figure 7 ). Safa also found only a slight (19%) inhibition of azidopine labelling by a 200-fold molar excess of another anthracycline, namely doxorubicin. This inhibition pattern of azidopine photolabelling is in agreement with results in Figure 6 where both vincristine and verapamil significantly increase azidopine accumulation in EHR2/DNR + but not EHR2 cells while daunorubicin has no effect. Furthermore, although verapamil at a 5-fold molar excess increases daunorubicin accumulation in EHR2/DNR + at least 400% (Friche et al., 1987) , daunorubicin does not increase verapamil accumulation even at 10-fold molar excess (Figure 3) , a result which is in agreement with Kessel (1986) . Vincristine however, whose accumulation in EHR2/DNR + cells is increased at least 500% by a 10-fold molar excess of verapamil (Sehested et al., 1989b) is only able to increase verapamil accumulation by 37% at a similar molar excess (Figure 3) . Thus, daunorubicin appears to interact differently with Pglycoprotein in EHR2/DNR + cells compared to azidopine, verapamil and vincristine.
In conclusion, though azidopine and verapamil are substrates for P-glycoprotein in EHR2/DNR + cells and could thereby modify P-glycoprotein function, they do not themselves follow the MDR efflux pathway to any detectable degree in these cells. 
